Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Kinetics of rubidium-82 after coronary occlusion and reperfusion. Assessment of patency and viability in open-chested dogs.
R A Goldstein
R A Goldstein
Published April 1, 1985
Citation Information: J Clin Invest. 1985;75(4):1131-1137. https://doi.org/10.1172/JCI111807.
View: Text | PDF
Research Article

Kinetics of rubidium-82 after coronary occlusion and reperfusion. Assessment of patency and viability in open-chested dogs.

  • Text
  • PDF
Abstract

Currently available noninvasive techniques are unable to rapidly assess artery patency and tissue viability during acute myocardial infarction. In prior studies, rubidium-82 (Rb-82), a short-lived positron emitter obtained from a generator, was validated as an indicator of flow with a model that included the rate constants for transfer into and out of the cell. Accordingly, in the current study, 20 open-chested dogs with experimental infarction were studied serially at base line, after coronary occlusion, and at reperfusion. Time-activity curves acquired with beta probes on the epicardial surface were used to measure flow and net transfer of rubidium. Flow decreased to 0.41 +/- 0.08 ml/min per gram during occlusion and increased to 2.73 +/- 0.56 ml/min per gram in potentially viable ischemic tissue, whereas flows were 0.32 +/- 0.08 during occlusion (P less than 0.05 vs. viable) and 1.58 ml/min per gram (P less than 0.002 vs. viable) in irreversibly injured tissue. The transfer rate constant for Rb-82, kT, at base line was +1.22 +/- 0.60 X 10(-3) s-1 and did not change significantly during occlusion in viable vs. nonviable samples (+1.41 +/- 1.27 vs. +0.93 +/- 1.51 X 10(-3) s-1, respectively), except that 4 out of 11 nonviable tissue samples had negative kTs. At reperfusion, viable myocardial samples were all positive (+1.26 +/- 1.58 X 10(-3) s-1), whereas all irreversibly injured tissues had a negative kT, indicating leakage of tracer (-1.50 +/- 1.10 X 10(-3) s-1, P less than 0.001). This study suggests that Rb-82 time-activity curves can be useful to determine patency of an infarct related artery and potential viability after reperfusion during myocardial infarction.

Authors

R A Goldstein

×

Full Text PDF

Download PDF (1.19 MB)

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts